Paying for Tissue: The Case of WI-38

In their Policy Forum “Paying patients for their tissue: the legacy of Henrietta Lacks” (6 July, p. [37][1]), R. D. Truog et al. overlook the L929 cell line, which, contrary to their statement about HeLa, was the first immortal cell line ([ 1 ][2]). Also overlooked are the commercial uses and